Results 141 to 150 of about 3,279 (223)

A Single-Centre Canadian Cost Analysis for the Care and Management of Injection Drug Use-Associated Infective Endocarditis Requiring Cardiac Surgery. [PDF]

CJC Open
Brown AN, Stevens K, Kim T, Hemmati S, Koury H, Sandhu J, Harten C, Sembo TWS, Kent WDT, Adams C, Hassanabad AF.   +10 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Hybrid CNN-GCN framework for brain tumor MRI classification: A graph-based approach to smart healthcare diagnostics. [PDF]

J Appl Clin Med Phys
Alkasasbeh MS, Ibnaouf KH, Ahmed NM, Rahman AA, Abbas DN, Al Tawil A, Idriss H, Alkasasbeh HT.   +7 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Emerging innovation, artificial intelligence, and digital technology in esophagology. [PDF]

Ann N Y Acad Sci
Shah ED, Chiang AL, Yip HC, Marescaux J, Swanstrom L, Reddy RM, Visaggi P, Lynch KL.   +7 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Heteroatom-doped MXene quantum dots for selective transition metal ion sensing: from atomic-level design to intelligent and deployable platforms. [PDF]

RSC Adv
Daoud E, Imad Najm B, Salim Waleed O, Shukla MB, M M R, Sasikumar Y, Sharma V, Aldulaimi A, Smaeilpour S.   +8 more
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Artificial intelligence in healthcare: applications, challenges, and future directions. A narrative review informed by international, multidisciplinary expertise. [PDF]

Front Digit Health
Mohajer-Bastami A, Moin S, Ahmad S, Ahmed AR, Pouwels S, Hajibandeh S, Yang W, Parmar C, Kermansaravi M, Khalil M, Khalid AW, Khamise A, Rawaf D, Hosseini F, Agarwal A, Lala A, Ahmed S, Patel B, Fyntanidou B, Egan R, Mougiakakou SG, Jakob DA, Ribordy V, Hautz WE, Exadaktylos AK.   +24 more
europepmc   +1 more source

Astrocyte heterogeneity in brain metastases

Molecular Oncology, EarlyView.
Astrocytes emerge as pivotal regulators of metastatic colonization, survival, immune remodeling, and therapy response associated with an increasing heterogeneity that requires spatially and longitudinally resolved approaches to uncover regulatory programs and guide context‐specific therapies.
Carolina Hernández‐Oliver, Neibla Priego, Manuel Valiente   +2 more
wiley   +1 more source